Madrigal Pharmaceuticals
Commercializes Rezdiffra and develops combination therapies for MASH.
Something off on this page? Send us feedback.
Breakdown13F · Form 4
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 23.10M · Float —
Float — provider float is below the insider stake.
The provider's float is smaller than the insider stake it should exclude, so it is not shown.
Institutions13F, as of Jun 30, 2026
437 holders · 32.99M shares · 79 new positions · 220 increased · 136 reduced · 45 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 2.14M | 9.28% | +1.4K | Aug 14, 2026 |
| RTW Investments, LP | 1.99M | 8.63% | 0 | Aug 14, 2026 |
| Jupiter Topco LLC | 1.94M | 8.38% | +1.94Mnew | Aug 14, 2026 |
| Avoro Capital Advisors LLC | 1.83M | 7.94% | +15.2K | Aug 14, 2026 |
| Paulson & Co. Inc. | 1.34M | 5.80% | −52.2K | Aug 14, 2026 |
| BlackRock, Inc. | 1.20M | 5.20% | −359.2K | Aug 7, 2026 |
| Vanguard Capital Management LLC | 835.7K | 3.62% | +8.5K | Aug 13, 2026 |
| Wellington Management Group LLP | 825.7K | 3.57% | +130.8K | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Roderick Wong, M.D.incl. RTW Investments, LP | 9.20% | 1.99M | 13G | Nov 14, 2024 ↗ |
| Janus Henderson Group PLC | 8.80% | 2.02M | 13G | May 15, 2026 ↗ |
| Paul A Friedman, M.D. | 7.80% | 1.81M | 13D | Dec 12, 2025 ↗ |
| Rebecca Taub, M.D. | 7.80% | 1.81M | 13D | Dec 12, 2025 ↗ |
| Paulson & Co. Inc. | 6.10% | 1.39M | 13G | May 15, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Baker Bros. Advisors LP | director | 1.95M | 8.44% | Jun 18, 2026 |
| Rebecca Taub | director | 452.7K | 1.96% | Jun 18, 2026 |
| Fred B. Craves | director | 361.1K | 1.56% | Mar 14, 2025 |
| William John Sibold | director, officer: President and CEO | 209.3K | 0.91% | Jul 20, 2026 |
| Paul A. Friedman | director | 187.2K | 0.81% | Jan 13, 2026 |
| Richard S. Levy | director | 22.5K | 0.10% | Jun 18, 2026 |
| Carole Huntsman | officer: Chief Commercial Officer | 12.7K | 0.05% | Mar 6, 2026 |
| Mardi Dier | officer: EVP and CFO | 12.5K | 0.05% | Mar 6, 2026 |
| Shannon T. Kelley | officer: General Counsel | 11.5K | 0.05% | Aug 20, 2026 |
| David Soergel | officer: Chief Medical Officer | 10.0K | 0.04% | Jun 1, 2026 |
2 ten-percent owners hold 250.3K shares by Form 4, outside the officers-and-directors figure above · 28 people have not refiled in the last 18 months (226.8K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 17, 2026 | Shannon T. Kelleyofficer: General Counsel | Sale | 664 | $514.97 | 11,474 |
| Jul 20, 2026 | William John Sibolddirector, officer: President and CEO | Sale · 10 lots | 2,500 | $547.30 | 209,329 |
| Jun 1, 2026 | David Soergelofficer: Chief Medical Officer | Sale | 1,042 | $495.74 | 10,033 |
| May 22, 2026 | Richard S. Levydirector | Sale · 12 lots | 5,682 | $515.44 | 22,015 |
| May 18, 2026 | David Soergelofficer: Chief Medical Officer | Sale | 844 | $515.90 | 11,075 |
| Mar 6, 2026 | Rebecca Taubdirector | Sale | 491 | $431.94 | 452,213 |
| Mar 6, 2026 | Carole Huntsmanofficer: Chief Commercial Officer | Sale | 419 | $431.94 | 12,692 |
| Mar 6, 2026 | Shannon T. Kelleyofficer: General Counsel | Sale | 360 | $431.94 | 12,138 |
| Mar 6, 2026 | William John Sibolddirector, officer: President and CEO | Sale | 1,663 | $431.94 | 161,829 |
| Mar 6, 2026 | Mardi Dierofficer: EVP and CFO | Sale · 12 lots | 1,982 | $430.87 | 12,490 |
CongressHouse and Senate disclosures
Not reported.